Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome.
angiotensin-converting enzyme inhibitors
hypertension
insulin sensitivity
pleiotropic effects
polycystic ovary syndrome
risk factors
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
07
03
2023
accepted:
02
05
2023
medline:
14
8
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
ppublish
Résumé
Women with polycystic ovary syndrome (PCOS), the most common endocrinopathy in reproductive age, are characterized by increased cardiometabolic risk. Similar hormonal and metabolic changes were found in their siblings. The purpose of our study was to compare blood pressure-lowering and pleiotropic effects of lisinopril between sisters of women with PCOS and their unrelated peers. The study included two age-, body mass index-, and blood pressure-matched groups of women with grade 1 hypertension: 26 sisters of PCOS probands (Group 1) and 26 individuals without a family history of PCOS (Group 2), receiving 10-40 mg of lisinopril daily. Blood pressure, glucose homeostasis markers, plasma levels of lipids (androgens, estradiol, high-sensitivity C-reactive protein (hsCRP), homocysteine, fibrinogen, and uric acid), and urinary albumin-to-creatinine ratio (UACR) were measured before lisinopril treatment and 6 months later. At baseline, the study groups differed in insulin sensitivity, testosterone, free androgen index (FAI), hsCRP, homocysteine, and UACR. Blood pressure-lowering properties of lisinopril did not differ between the groups. The decrease in homocysteine and UACR, although observed in both groups, was stronger in Group 2 than in Group 1. Only in women without a family history of PCOS lisinopril improved insulin sensitivity and reduce hsCRP, fibrinogen, and uric acid. The remaining markers did not change throughout the study. Cardiometabolic effects of lisinopril correlated with testosterone, free androgen index, and changes in insulin sensitivity. The obtained results suggest that cardiometabolic effects of lisinopril may be slightly less pronounced in sisters of women with PCOS than in women without a family history of this disorder.
Substances chimiques
Androgens
0
Lisinopril
E7199S1YWR
C-Reactive Protein
9007-41-4
Uric Acid
268B43MJ25
Testosterone
3XMK78S47O
Fibrinogen
9001-32-5
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1052Informations de copyright
© 2023, The American College of Clinical Pharmacology.
Références
Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321-336. doi:10.1097/AOG.0000000000002698
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-284. doi:10.1038/nrendo.2018.24
Guan C, Zahid S, Minhas AS, et al. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertil Steril. 2022;117(5):924-935. doi:10.1016/j.fertnstert.2022.03.009
Cooney LG, Dokras A. Cardiometabolic risk in polycystic ovary syndrome: current guidelines. Endocrinol Metab Clin North Am. 2021;50(1):83-95. doi:10.1016/j.ecl.2020.11.001
Lenarcik A, Bidzinska-Speichert B, Tworowska-Bardzinska U, Krepula K. Hormonal abnormalities in first-degree relatives of women with polycystic ovary syndrome (PCOS). Endokrynol Pol. 2011;62(2):129-133.
Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(5):2031-2036. doi:10.1210/jc.2002-021499
Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95(25):14956-14960. doi:10.1073/pnas.95.25.14956
Yilmaz B, Vellanki P, Ata B, Yildiz BO. Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018;109(2):356-364. doi:10.1016/j.fertnstert.2017.10.018
Yilmaz B, Vellanki P, Ata B, Yildiz BO. Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018;110(3):523-533.e14. doi:10.1016/j.fertnstert.2018.04.024
Yilmaz M, Bukan N, Ersoy R, et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod. 2005;20(9):2414-2420. doi:10.1093/humrep/dei070
Karthik S, Vipin VP, Kapoor A, Tripathi A, Shukla M, Dabadghao P. Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome. Hum Reprod. 2019;34(8):1559-1566. doi:10.1093/humrep/dez104
Krysiak R, Basiak M, Szkróbka W, Okopień B. The impact of telmisartan on cardiometabolic risk factors in hypertensive male siblings of women with polycystic ovary syndrome. J Clin Pharmacol. 2021;61(9):1165-1173. doi:10.1002/jcph.1872
Krysiak R, Basiak M, Okopień B. Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia: a pilot study. J Cardiovasc Pharmacol. 2021;78(5):e738-e742. doi:10.1097/FJC.0000000000001113
Cohen PR, Kurzrock R. Polycystic ovary syndrome in men. Med Hypotheses. 2017;103(1):64. doi:10.1016/j.mehy.2017.04.010
Diver M. Laboratory measurement of testosterone. Front Horm Res. 2009;37:21-31. doi:10.1159/000175841
Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81-151. doi:10.1210/er.2010-0013
Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E. Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril. 2002;77(3):526-528. doi:10.1016/s0015-0282(01)03210-1
Kotsis V, Antza C, Doundoulakis I, Stabouli S. Markers of early vascular ageing. Curr Pharm Des. 2017;23(22):3200-3204. doi:10.2174/1381612823666170328142433
Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev. 2011;12(5):e282-e289. doi:10.1111/j.1467-789X.2010.00807.x
Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A. Indirect insulin resistance detection: current clinical trends and laboratory limitations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163:187-199. doi:10.5507/bp.2019.021
Deng D, Yan N. GLUT, SGLT, and SWEET: structural and mechanistic investigations of the glucose transporters. Protein Sci. 2016;25(3):546-558. doi:10.1002/pro.2858
Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148(1):241-251. doi:10.1210/en.2006-0692
Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998;182(1-2):169-175.
Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol. 2003;196(1):171-179. doi:10.1002/jcp.10294
Krishnan A, Muthusami S, Periyasamy L, Stanley JA, Gopalakrishnan V, Ramachandran I. Effect of DHT-induced hyperandrogenism on the pro-inflammatory cytokines in a rat model of polycystic ovary morphology. Medicina. 2020;56(3):100. doi:10.3390/medicina56030100
Hughes TK, Fulep E, Juelich T, Smith EM, Stanton GJ. Modulation of immune responses by anabolic androgenic steroids. Int J Immunopharmacol. 1995;17:857-863. doi:10.1016/0192-0561(95)00078-x
Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581. doi:10.1152/physrev.00024.2005
Haeckel R, Wosniok W. The phenomenon of regression-toward-the-mean. Clin Chem Lab Med. 2004;42(2):241-242. doi:10.1515/CCLM.2004.044